Last reviewed · How we verify

NCT05276856

Recovery Rate in Secondary Hypothyroidism

Recruiting now Last updated 21 August 2024
What this trial tests

trial testing Levothyroxine in Secondary Hypothyroidism in 90 participants. Currently enrolling.

Timeline
4 April 2022
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorNova Scotia Health Authority
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment90
Start date4 April 2022
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Nova Scotia Health Authority — full company profile →

Who can join

18 and older, any sex, with Secondary Hypothyroidism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this project is to assess the rate of recovery of secondary hypothyroidism in patients with pituitary disorders.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Levothyroxine

Trials testing the same drug.

Other Nova Scotia Health Authority trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05276856.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing